Research suggests that cannabis may help treat Inflammatory bowel diseases. Photo credit: Envato.
Doctors and healers across many cultures have used cannabis for centuries to treat a long list of ailments from nausea to expelling tapeworms. But It looks like it might be time to add a few more ailments to the list.
Recent studies show cannabis may aid in the treatment and symptom management for certain inflammatory bowel diseases (IBD) such as Irritable Bowel Syndrome (IBS), Crohn’s disease and ulcerative colitis.
Gastrointestinal ailments plague people of all ages, races, creeds and genders. Experts estimate that IBS affects anywhere from 25 to 45 million Americans. The CDC estimates another three million suffer from a form of IBD — either Crohn’s disease or ulcerative colitis.
Some research points to cannabis as a therapeutic remedy for a wide range of IBDs.
More specifically, researchers suggest the key to understanding the therapeutic link between cannabis and IBDs lies within the endocannabinoid system (ECS).
The Endocannabinoid System
The ECS is a cell-signalling system which plays an important role in regulating sleep, immune responses and more. It’s primary function is to maintain homeostasis within the body, a.k.a “the Goldilocks zone” — because everything feels just right.
It is composed of three core components: endocannabinoids, receptors and enzymes. Endocannabinoids are molecules similar to cannabinoids, except human and animal bodies create them. “Endo” comes from the Greek word “endon” meaning “within.”
“People say [endocannabinoids are] like the body’s own marijuana. A structural chemist, they might take some objection to that because the [molecular] structures don’t look that much alike. But functionally, which is what a physiologist thinks about, the physiology of how anandamide binds to and changes cellular activity binding a cannabinoid receptor is actually quite similar to THC,” he told Project CBD.
Receptors are located throughout the body. Endocannabinoids bind to the two main receptors — CB1 and CB2 — signaling the ECS that it’s time to work.
CB1 receptors are most abundant in the body’s nervous systems (central, peripheral and enteric). CB2 receptors are most prevalent in the immune system. Although, both are found throughout the body, according to Leafly.
Which receptors endocannabinoids bind to depends on the function the ECS is carrying out. For example, endocannabinoids might bind to CB1 receptors in the spinal nerve to relieve pain. Or they might bind to CB2 receptors in immune cells to alert the body to inflammation.
Lastly, enzymes break down endocannabinoids once they’ve completed their desired task.
Cannabis and Gut Health
When cannabinoids like THC enter the body, they bind to receptors just like endocannabinoids. However, cannabinoids can bind to CB1 and CB2 receptors all over the body. That’s why sometimes cannabis is used to relieve pain, stimulate appetite and/or induce drowsiness, according to Healthline.
Though CB1 receptors are mainly located in the nervous systems and CB2 receptors in the immune system; researchers found both types of receptors in the gastrointestinal system as well, including all layers of intestinal sections.
Because scientists discovered the ECS less than 30 years ago, they know little about it compared to other bodily systems. And with cannabis still a Schedule I Controlled Substance, scientists have conducted even less research on the connection between the two.
However, in recent years some researchers have concluded that there is a rather promising relationship between cannabis, the ECS, and gut health.
In 2015, a team of researchers in Canada discovered that a daily regimen of THC improved the gut microbiome health in mice on a high-fat diet after three to four weeks. The resulting gut microbiome health resembled that of mice fed a healthy, balanced diet.
Researchers in 2017 studied cannabis and the human gut microbiome, comparing 19 lifetime cannabis users and 20 non-users. They discovered that the cannabis users’ gut microbiome contained bacteria populations associated with higher caloric intake but lower BMI. Although researchers thought diet may have played a role, according to Project CBD.
Though there is a lack of viable studies on the topic, the evidence thus far suggests that the ECS does interact with gut bacteria, and that cannabinoids like THC or CBD may modify or even improve gut microbiome health.
Some attribute the potential viability of cannabis as a treatment for IBDs to the plant’s anti-inflammatory properties. [story continues on next page]